1. LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis. (23rd January 2014) Authors: Keystone, E.; Taylor, P.; Genovese, M.; Schlichting, D.; Beattie, S.; Gaich, C.; Fidelus Gort, R.; Luchi, M.; Macias, W.L. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0166 Safety Profile of Baricitinib in Patients with Active RA: An Integrated Analysis. (15th July 2016) Authors: Smolen, J.; Genovese, M.; Takeuchi, T.; Hyslop, D.; Macias, W.L.; Rooney, T.P.; Chen, L.; Dickson, C.; Riddle, J.; Cardillo, T.; Winthrop, K. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0182 Ex Vivo Functional Comparison of Baricitinib and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations. (15th July 2016) Authors: McInnes, I.; Higgs, R.; Rocha, G.; Zhang, X.; Lee, J.; Wehrman, T.; Macias, W.L.; Zuckerman, S.; Taylor, P. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0198 Baricitinib Effects on Lipid and NMR-Measured Lipoprotein Profiles in A Phase 3 Study in Patients with Rheumatoid Arthritis. (15th July 2016) Authors: Taylor, P.; Keystone, E.; Tanaka, Y.; van der Heijde, D.; Zhong, J.; Thanabalasundrum, S.; Ruotolo, G.; Schlichting, D.; Rooney, T.P.; Macias, W.L.; Zuckerman, S.; de Bono, S.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 257 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THU0201 Weak Correlation between A Multi-Biomarker Disease Activity Score and Clinical Response with Baricitinib in A Phase 2b Study in Rheumatoid Arthritis. (15th July 2016) Authors: Fleischmann, R.; Genovese, M.; Keystone, E.; Weinblatt, M.; Rancourt, J.; Nantz, E.; Schlichting, D.; Zuckerman, S.; Macias, W.L.; Taylor, P. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0209 Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in A Phase 3 Study (RA-BEAM). (15th July 2016) Authors: Tanaka, Y.; Fleischmann, R.; Schiff, M.; Takeuchi, T.; Keystone, E.; Weinblatt, M.; Zuckerman, S.; Issa, M.; Thanabalasundrum, S.; Augendre-Ferrante, B.; de Bono, S.; Schlichting, D.; Rooney, T.P.; Macias, W.L.; Taylor, P. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗